OTLK — Outlook Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1649989 ·
Last close
$0.98
Market Cap
$182.70M
52W High
$1.88
52W Low
$0.21
ADV30
13,527,433
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 127,439 | -21,888 | -14,026,987 | -4,453,081 | 21,892,406 | 7,748,226 | 50,887,177 |
| Dec 2025 | -1,207,833 | -1,237,459 | -13,483,952 | -23,058,135 | 18,238,574 | 8,677,424 | 56,788,039 |
| Sep 2025 | -91,787 | -1,008,302 | -17,314,606 | -13,292,769 | 18,584,183 | 8,083,085 | 50,771,844 |
| Jun 2025 | 1,505,322 | 1,065,507 | -15,748,680 | -20,152,502 | 22,391,540 | 8,900,814 | 59,581,265 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,045,522
Investing CF
—
Financing CF
$47,237,435
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.48
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-633,220,979
Inventory
$3,344,242
Receivables
$2,719,828
ST Investments
—
EBIT TTM
$-62,197,332
Pretax Income TTM
$-62,511,116
Interest Exp TTM
$313,507
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$333,141
EBITDA
$-60,454,584
Free Cash Flow
$-25,471,416
Enterprise Value
$137,474,784
Total Cash
$7,748,226
Total Debt
$27,187,960
Shares Out
186,996,998
Trailing EPS
$-1.13
Book Value
$-0.28
ROE
—
ROA
-184.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 1,413,535 | -67,061,666 | -62,424,863 | 18,584,183 | 50,771,844 | — | -51,829,437 |
| Sep 2024 | 0 | -71,703,235 | -75,366,714 | 28,823,154 | 101,899,664 | — | -68,793,858 |
| Sep 2023 | 0 | -53,126,382 | -58,982,668 | 32,300,601 | 46,738,378 | — | -42,973,398 |
| Sep 2022 | 0 | -63,070,753 | -66,052,264 | 28,527,751 | 19,791,180 | — | -56,674,559 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.16
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VYGR | Voyager Therapeutics, Inc. | $183.08M | $3.03 | — |
| DTIL | PRECISION BIOSCIENCES INC | $180.36M | $6.99 | — |
| ACOG | Alpha Cognition Inc. | $180.29M | $8.28 | — |
| HUMA | Humacyte, Inc. | $176.07M | $0.65 | — |
| PLX | Protalix BioTherapeutics, Inc. | $190.95M | $2.37 | — |
News headlines (Yahoo Finance, 1h cache)
Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG
2026-07-27 17:45 · Yahoo
Outlook Therapeutics wins FDA approval for Lytenava in wet AMD
2026-07-27 11:13 · Yahoo
Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMD
2026-07-27 11:12 · Yahoo
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
2026-07-24 18:40 · Yahoo
Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In
2026-06-16 20:08 · Yahoo
Why Outlook Therapeutics (OTLK) Is Up 57.1% After FDA Validates LYTENAVA Efficacy and BLA Resubmission
2026-06-14 13:08 · Yahoo
OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside
2026-07-27 06:47 · Yahoo
OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab
2026-07-24 23:47 · Yahoo
OTLK Stock Generates Buzz Ahead Of FDA Decision On Wet AMD Therapy – Retail Says Favorable Verdict Could Cause A ‘Big Boom’
2026-07-23 17:00 · Yahoo
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision
2026-06-16 17:47 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-07-29 15:19:37 | 2026-07-29 | Sukhtian Faisal Ghiath | Dir | P - Purchase | 1.05 | 95398 | 99996 |